FinTrust Capital Advisors’s DexCom DXCM Stock Holding History

FinTrust Capital Advisors’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$73.1K	Sell	1,091 -37	-3%	-$3.04K	0.01%	494
2024 Q2	$128K	Buy	1,128 +12	+1%	+$1.52K	0.02%	363
2024 Q1	$155K	Hold	1,116	–	–	0.03%	323
2023 Q4	$138K	Buy	1,116 +580	+108%	+$59.3K	0.03%	318
2023 Q3	$50K	Buy	536 +312	+139%	+$35.2K	0.01%	453
2023 Q2	$25.4K	Hold	224	–	–	0.01%	595
2023 Q1	$25.4K	Hold	224	–	–	0.01%	593
2022 Q4	$25.4K	Hold	224	–	–	0.01%	592
2022 Q3	$22K	Hold	224	–	–	0.01%	697
2022 Q2	$19K	Buy	224 +24	+12%	+$2.19K	﹤0.01%	738
2022 Q1	$26K	Hold	200	–	–	0.01%	699
2021 Q4	$27K	Hold	200	–	–	0.01%	658
2021 Q3	$27K	Hold	200	–	–	0.01%	659
2021 Q2	$21K	Hold	200	–	–	0.01%	748
2021 Q1	$18K	Buy	200 +40	+25%	+$3.75K	0.01%	743
2020 Q4	$15K	Sell	160 -560	-78%	-$50K	﹤0.01%	735
2020 Q3	$74	Buy	720 +36	+5%	+$3.76K	0.01%	419
2020 Q2	$69K	Sell	684 -400	-37%	-$35.8K	0.03%	415
2020 Q1	$73K	Hold	1,084	–	–	0.04%	347
2019 Q4	$59K	Buy	+1,084	New	+$51.4K	0.02%	408

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

FinTrust Capital Advisors's DXCM Position: Q3 2024 in Review

FinTrust Capital Advisors reduced its DexCom (DXCM) stake by 3.3% in Q3 2024, selling an estimated $3.04K and leaving 1,091 shares worth $73.1K. The position accounts for 0.01% of the portfolio, ranked #494.

FinTrust Capital Advisors first reported a position in DXCM in Q4 2019 and has held it in 20 quarters since. The position peaked at $155K in Q1 2024. 889 funds tracked by Wall St. Rank hold DXCM as of Q3 2024.

FinTrust Capital Advisors held 1,091 shares of DexCom worth $73.1K as of Q3 2024.
FinTrust Capital Advisors sold 37 DexCom shares in Q3 2024, an estimated $3.04K.
DexCom made up 0.01% of FinTrust Capital Advisors's portfolio in Q3 2024, its #494 holding.
FinTrust Capital Advisors first reported a position in DexCom in Q4 2019 and has held it in 20 quarters since.
FinTrust Capital Advisors's DexCom position peaked at $155K in Q1 2024.
889 funds tracked by Wall St. Rank held DexCom as of Q3 2024.

Based on FinTrust Capital Advisors's 13F filing for Q3 2024, filed 11 Oct 2024.